Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Public ClinicalTrials.gov record NCT02635672. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multicenter Phase I Dose Escalation Study to Characterize Safety, Tolerability, Preliminary Anti-tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of VIP152 (BAY 1251152) as Monotherapy or Combination Therapy in Subjects With Advanced Cancer.
Study identification
- NCT ID
- NCT02635672
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Vincerx Pharma, Inc.
- Industry
- Enrollment
- 110 participants
Conditions and interventions
Conditions
Interventions
- Keytruda Drug
- VIP152 (BAY 1251152) Drug
- VIP152 (BAY 1251152) 15 mg Drug
- VIP152 (BAY 1251152) 30 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 9, 2016
- Primary completion
- Nov 10, 2024
- Completion
- Nov 10, 2024
- Last update posted
- Nov 14, 2024
2016 – 2024
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group | Springdale | Arkansas | 72762 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40202 | — |
| Maryland Oncology Hematology | Silver Spring | Maryland | 20904 | — |
| John Theurer Cancer Center | Hackensack | New Jersey | 07601 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45219 | — |
| Willamette Valley Cancer Institute | Eugene | Oregon | 97401 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Avera Health | Sioux Falls | South Dakota | 57105 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| NEXT Oncology | Austin | Texas | 78758 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| NEXT Oncology | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02635672, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 14, 2024 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02635672 live on ClinicalTrials.gov.